154 related articles for article (PubMed ID: 14982154)
21. Interaction of trypsin with multilamellar vesicles of soybean lipids.
Martynova OM; Tiourina OP; Selischeva AA; Sorokoumova GM; Shvets VI; Larionova NI
Biochemistry (Mosc); 2000 Sep; 65(9):1049-54. PubMed ID: 11042497
[TBL] [Abstract][Full Text] [Related]
22. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.
Porter CJ; Trevaskis NL; Charman WN
Nat Rev Drug Discov; 2007 Mar; 6(3):231-48. PubMed ID: 17330072
[TBL] [Abstract][Full Text] [Related]
23. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing.
Espina R; Yu L; Wang J; Tong Z; Vashishtha S; Talaat R; Scatina J; Mutlib A
Chem Res Toxicol; 2009 Feb; 22(2):299-310. PubMed ID: 18980340
[TBL] [Abstract][Full Text] [Related]
24. Analytical strategies for identifying drug metabolites.
Prakash C; Shaffer CL; Nedderman A
Mass Spectrom Rev; 2007; 26(3):340-69. PubMed ID: 17405144
[TBL] [Abstract][Full Text] [Related]
25. Metabolism of defined structured triglyceride particles compared to mixtures of medium and long chain triglycerides intravenously infused in dogs.
Simoens Ch; Deckelbaum RJ; Carpentier YA
Clin Nutr; 2004 Aug; 23(4):665-72. PubMed ID: 15297104
[TBL] [Abstract][Full Text] [Related]
26. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis.
Lindon JC; Holmes E; Bollard ME; Stanley EG; Nicholson JK
Biomarkers; 2004; 9(1):1-31. PubMed ID: 15204308
[TBL] [Abstract][Full Text] [Related]
27. Mass spectrometry: from proteomics to metabolomics and lipidomics.
Griffiths WJ; Wang Y
Chem Soc Rev; 2009 Jul; 38(7):1882-96. PubMed ID: 19551169
[TBL] [Abstract][Full Text] [Related]
28. A centralized approach to tandem mass spectrometry method development for high-throughput ADME screening.
Whalen K; Gobey J; Janiszewski J
Rapid Commun Mass Spectrom; 2006; 20(10):1497-503. PubMed ID: 16628559
[TBL] [Abstract][Full Text] [Related]
29. Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study.
Chen CT; Liu Z; Ouellet M; Calon F; Bazinet RP
Prostaglandins Leukot Essent Fatty Acids; 2009; 80(2-3):157-63. PubMed ID: 19237271
[TBL] [Abstract][Full Text] [Related]
30. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
31. Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
Price DA; Blagg J; Jones L; Greene N; Wager T
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):921-31. PubMed ID: 19519283
[TBL] [Abstract][Full Text] [Related]
32. Applications of high-throughput ADME in drug discovery.
Kassel DB
Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
[TBL] [Abstract][Full Text] [Related]
33. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
34. Modeling promiscuity based on in vitro safety pharmacology profiling data.
Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
[TBL] [Abstract][Full Text] [Related]
35. Mass spectrometry analysis of new chemical entities for pharmaceutical discovery.
Fang AS; Miao X; Tidswell PW; Towle MH; Goetzinger WK; Kyranos JN
Mass Spectrom Rev; 2008; 27(1):20-34. PubMed ID: 18033735
[TBL] [Abstract][Full Text] [Related]
36. Metabonomics: systems biology in pharmaceutical research and development.
Lindon JC; Holmes E; Nicholson JK
Curr Opin Mol Ther; 2004 Jun; 6(3):265-72. PubMed ID: 15264428
[TBL] [Abstract][Full Text] [Related]
37. A generic fast solid-phase extraction high-performance liquid chromatography/mass spectrometry method for high-throughput drug discovery.
Gao L; Cheng X; Zhang J; Burns DJ
Rapid Commun Mass Spectrom; 2007; 21(21):3497-504. PubMed ID: 17922486
[TBL] [Abstract][Full Text] [Related]
38. Strategies for dealing with reactive intermediates in drug discovery and development.
Nassar AE; Lopez-Anaya A
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
[TBL] [Abstract][Full Text] [Related]
39. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines.
Alavijeh MS; Palmer AM
IDrugs; 2004 Aug; 7(8):755-63. PubMed ID: 15334309
[TBL] [Abstract][Full Text] [Related]
40. Use of (1)H NMR to facilitate solubility measurement for drug discovery compounds.
Lin M; Tesconi M; Tischler M
Int J Pharm; 2009 Mar; 369(1-2):47-52. PubMed ID: 19073245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
